In our previous preclinical work, we generated IL-2/15 activated and expanded primary CAR33-NK cells that showed strong antileukemic activity against CD33+ AML cells in vitro and in a xenograft model in vivo19. The gene discussed is IL2; the disease is acute myeloid leukemia.